---
figid: PMC11241496__ijms-25-06967-g002
figtitle: Targeted therapies in RAS-RAF-MAPK pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11241496
filename: ijms-25-06967-g002.jpg
figlink: /pmc/articles/PMC11241496/figure/F2
number: F2
caption: 'Targeted therapies in RAS-RAF-MAPK pathway. Approved treatments and treatments
  under investigation in RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. Treatments in
  ongoing clinical trials are marked with an asterisk (not approved by the FDA). Abbreviations:
  T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan'
papertitle: 'Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating
  Hallmarks of Cancer'
reftext: Clara Salva de Torres, et al. Int J Mol Sci. 2024 Jul;25(13).
year: '2024'
doi: 10.3390/ijms25136967
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: colorectal cancer | hallmarks of cancer | drug development | cancer biology
  | targeted therapies | immune checkpoint inhibitors
automl_pathway: 0.9532918
figid_alias: PMC11241496__F2
figtype: Figure
redirect_from: /figures/PMC11241496__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11241496__ijms-25-06967-g002.html
  '@type': Dataset
  description: 'Targeted therapies in RAS-RAF-MAPK pathway. Approved treatments and
    treatments under investigation in RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways.
    Treatments in ongoing clinical trials are marked with an asterisk (not approved
    by the FDA). Abbreviations: T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ACVRL1
  - ALK
  - SLPI
  - EGFR
  - ERBB3
  - ERBB4
  - ERBB2
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - RET
  - KRAS
  - NRAS
  - HRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MTOR
  - ROS
  - MET
  - RAS
  - MEK
  - Cancer
---
